Total and regional airway deposition of orally inhaled drugs is determined by the complex interaction of numerous patient- and inhaler-related factors. Particle size (aerodynamic diameter) is considered to be the most important of the aerosol-related factors(1–3); however, the medical literature lacks standard nomenclature to distinguish aerosol particle sizes. There are clear differences in particle behavior and deposition according to size, and hence we believe a strong rationale for clearly denoting the aerosol particle size of orally inhaled, therapeutic aerosols, both in product descriptions and as part of the design and reporting of research in this area
Original languageEnglish
Pages (from-to)111-113
Number of pages3
JournalJournal of aerosol medicine and pulmonary drug delivery
Issue number2
Early online date28 Nov 2017
Publication statusPublished - 30 Apr 2018

Bibliographical note

Acknowledgements: The authors thank the other members of the Small Airways Study Group of the Respiratory Effectiveness Group who participated in discussions about nomenclature for therapeutic aerosol particle size: Dirkje Postma (University of Groningen, Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, the Netherlands, retired), Theresa Guilbert (Cincinnati Children's Hospital and Medical Center, Cincinnati, OH), Jonathan Grigg (Blizard Institute, Queen Mary University London, London, UK), and Wanda Phipatanakul (Boston Children's Hospital and Harvard Medical School, Boston, MA). They also thank Alison Chisholm of the Respiratory Effectiveness Group for moderating the steering committee meetings at which particle size nomenclature was discussed.


  • Letter to the Editor


Dive into the research topics of 'Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal'. Together they form a unique fingerprint.

Cite this